Logo
Unionpedia
Communication
Get it on Google Play
New! Download Unionpedia on your Androidâ„¢ device!
Install
Faster access than browser!
 

Adjuvant therapy and Tulrampator

Shortcuts: Differences, Similarities, Jaccard Similarity Coefficient, References.

Difference between Adjuvant therapy and Tulrampator

Adjuvant therapy vs. Tulrampator

Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. Tulrampator (developmental code names S-47445, CX-1632) is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by RespireRx Pharmaceuticals (formerly Cortex Pharmaceuticals) and Servier for the treatment of major depressive disorder (as an adjunct), Alzheimer's disease, dementia, and mild cognitive impairment.

Similarities between Adjuvant therapy and Tulrampator

Adjuvant therapy and Tulrampator have 2 things in common (in Unionpedia): Adverse effect, Dementia.

Adverse effect

In medicine, an adverse effect is an undesired harmful effect resulting from a medication or other intervention such as surgery.

Adjuvant therapy and Adverse effect · Adverse effect and Tulrampator · See more »

Dementia

Dementia is a broad category of brain diseases that cause a long-term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning.

Adjuvant therapy and Dementia · Dementia and Tulrampator · See more »

The list above answers the following questions

Adjuvant therapy and Tulrampator Comparison

Adjuvant therapy has 92 relations, while Tulrampator has 37. As they have in common 2, the Jaccard index is 1.55% = 2 / (92 + 37).

References

This article shows the relationship between Adjuvant therapy and Tulrampator. To access each article from which the information was extracted, please visit:

Hey! We are on Facebook now! »